27th Feb 2007 07:02
Oxford Biomedica PLC27 February 2007 For Immediate Release 27 FEBRUARY 2007 OXFORD BIOMEDICA: NOTICE OF FY2006 PRELIMINARY RESULTS Oxford, UK - 27 February 2007: Oxford BioMedica (LSE: OXB), the leading genetherapy company, announces that it will be releasing its preliminary results forthe twelve months ended 31 December 2006 on Tuesday, 6 March 2007. Analyst meeting: An analyst briefing will be held at 10:00 am on 6 March at theoffices of Buchanan Communications, 45 Moorfields, London EC2. Web cast: Simultaneously to the analyst briefing at 10.00 am, there will be alive audio web cast of the results presentation. To connect to the web castfacility, please go to the Company's website: http://www.oxfordbiomedica.co.uk/approximately 10 minutes (09:50 am) before the start of the briefing. This willalso be available for replay shortly after the presentation. -Ends- For further information, please contact:Oxford BioMedica plc: Tel: +44 (0)1865 783 000 Professor Alan Kingsman, Chief ExecutiveCity/Financial Enquiries: Tel: +44 (0)20 7466 5000 Lisa Baderoon/ Mark Court/ Mary-Jane Johnson BuchananCommunicationsScientific/Trade Press Enquiries: Tel: +44 (0)20 7268 3002 Gemma Price/ Holly Griffiths/ Katja StoutNorthbank Communications Notes to editors 1. Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment of novel gene-based therapeutics with a focus on oncology andneurotherapy. The Company was established in 1995 as a spin out from OxfordUniversity, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-houseclinical, regulatory and manufacturing know-how. In oncology, the pipelineincludes two clinical candidates and a preclinical targeted antibody therapy,which is being developed in collaboration with Wyeth. The Company has startedPhase III development of its lead cancer immunotherapy product, TroVax, in renalcancer and multiple Phase II trials in various cancer settings are ongoing orplanned. In neurotherapy, the Company's lead product, ProSavin, is expected toenter clinical trials in Parkinson's disease in 2007. The preclinical pipelineincludes gene-based products for vision loss, motor neuron disease and nerverepair. The Company is underpinned by over 80 patent families, which represent one ofthe broadest patent estates in the field. The Company has a staff ofapproximately 70 split between its main facilities in Oxford and its whollyowned subsidiary, BioMedica Inc, in San Diego, California. Oxford BioMedica hascorporate collaborations with Wyeth, Intervet, Sigma-Aldrich, Viragen, MolMed,and VIRxSYS; and has licensed technology to a number of companies includingMerck & Co, Biogen Idec, GSK and Pfizer. Further information is available at www.oxfordbiomedica.co.uk This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica